Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising treatments, particularly in advanced forms of numerous cancers like melanoma. By blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for CTLA-4, setting CD28 free to act unlimited. This blockade can re...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi, Amirali, Alilou, Sanam, Mirzaei, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985548/
https://www.ncbi.nlm.nih.gov/pubmed/33767992
http://dx.doi.org/10.3389/fonc.2021.624780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985548/
https://www.ncbi.nlm.nih.gov/pubmed/33767992
http://dx.doi.org/10.3389/fonc.2021.624780

Ejemplares similares